Gene editing stands at the forefront of scientific innovation, impacting sectors like healthcare and agriculture. However, the technology is limited by the existing tools used for altering DNA. Mandrake Bio, a pioneering company based in Bengaluru, is harnessing the power of generative AI to reshape the landscape of gene editing.
The Promise of Gene Editing
According to Tanay Lohia, the founder and chief editing officer of Mandrake Bio, “Every living thing runs on one set of instructions, the DNA; and for the first time in history we can rewrite it.” This revolutionary capability has the potential to address numerous genetic disorders. Conditions such as sickle cell disease and inherited blindness arise from DNA errors, yet most current treatments merely alleviate symptoms instead of targeting the root genetic issues.
Expanding Horizons Beyond Current Limitations
While gene editing is being explored for applications in cancer therapy and agricultural enhancement, its accessibility remains a challenge. Lohia points out that existing gene editing solutions are limited: “Today’s cures work for a handful of diseases, cost a fortune, and only function by editing cells outside the body; in agriculture, edited crops barely reach real fields.” This highlights the pressing need for more versatile and effective gene editing tools.
The CRISPR Challenge
Current gene editing tools like CRISPR offer high precision in cutting DNA. However, they have significant limitations: they are often too large for in vivo applications and struggle with intricate edits, such as the insertion of healthy genes. Mandrake Bio aims to overcome these hurdles by creating entirely new proteins tailored for gene editing, utilizing generative AI and first-principles biophysics.
A New Approach to Protein Design
Lohia emphasizes, “The next generation of gene editors won’t be discovered in nature, but will be designed.” Instead of repurposing existing enzymes, Mandrake Bio engineers proteins from the ground up, embedding essential characteristics such as compactness, precision, and control directly into each design. This innovative approach allows for rapid advancements in gene editing capabilities.
Closed-Loop Testing for Continuous Improvement
At the heart of Mandrake Bio’s strategy is a closed-loop testing methodology. Each protein design undergoes rigorous testing in the company’s in-house wet lab, with results constantly fed back into the AI models for refinement. Lohia describes this iterative process as a key component of their platform, where real-world data serves to enhance subsequent designs.
Engineering Discipline Over Discovery
“We treat editor development as an engineering discipline, not a discovery expedition,” Lohia explains. This mindset drastically reduces the time frame for enzyme engineering, compressing what would typically take years into mere weeks. As a result, the team can focus on a select group of promising candidates instead of sifting through thousands of less effective options.
Collaborative Ventures and Future Prospects
Mandrake Bio is actively pursuing a co-development model, partnering with companies across agriculture, therapeutics, and biotechnology. Their primary customers include firms dedicated to developing agricultural products and therapeutic solutions. Earlier this year, the startup secured approximately ₹16 crore in a pre-seed funding round, which is being utilized to validate its AI models against real-world data and improve its editing enzymes.
A Global Vision from India
The company’s aspirations extend beyond domestic borders. Lohia asserts, “We’re global by design. Disease and food security don’t belong to any one country, and an improved gene editor is valuable to all of humanity.” Despite its global ambitions, Mandrake Bio is rooted in India, allowing it to leverage scientific expertise while operating with lower capital requirements.
Conclusion
Mandrake Bio is on the cutting edge of gene editing, intertwining the realms of artificial intelligence and protein engineering. By redefining how gene editors are designed and tested, the company is not just pushing the boundaries of science but is also poised to make a significant impact on global health and agriculture. With its innovative approach, Mandrake Bio could well lead the next wave of breakthroughs in gene editing technology.
- Key Takeaways:
- Mandrake Bio utilizes AI to design proteins specifically for gene editing.
- The company employs a closed-loop testing system to refine its designs.
- Its approach focuses on engineering discipline, speeding up the development process.
- The startup emphasizes global accessibility to its innovations, addressing both health and food security.
- Future funding will support broader AI model development and lab infrastructure expansion.
Read more → www.thehindubusinessline.com